Addition of Venetoclax to Patients with Acute Myeloid Leukemia Relapsing after Treatment with Hypomethylating Agents. Multicenter Historical Prospective Study

Conclusions - the addition of venetoclax to patients with HMA-refractory AML may result in a substantial anti-leukemic activity, specifically in those achieving complete remission. This should be further tested in a well designed prospective trial.DisclosuresZuckerman: Cellect Biotherapeutics Ltd: Consultancy.
Source: Blood - Category: Hematology Authors: Tags: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster III Source Type: research